2020
Hepmarc (Protocol) Bradshaw D, Gilleece Y, Verma S, Abramowicz I, Bremner S, Perry N. Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone. BMJ Open. 2020 Jul 6;10(7):e035596. doi: 10.1136/bmjopen-2019-035596. PMID: 32636281; PMCID: PMC7342479. Read it here >
PIBIK (Protocol) Iwuji CC, Churchill D, Bremner S, Perry N, To Y, Lambert D, Bruce C, Waters L, Orkin C, Geretti AM. A phase IV randomised, open-label pilot study to evaluate switching from proteaseinhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial. BMC Infect Dis. 2020 Jul 20;20(1):524. doi: 10.1186/s12879-020-05240-y. PMID: 32689975; PMCID: PMC7370264. Read it here >
Reduce (Results) Macken L, Bremner S, Gage H, Touray M, Williams P, Crook D, Mason L, Lambert D, Evans CJ, Cooper M, Timeyin J, Steer S, Austin M, Parnell N, Thomson SJ, Sheridan D, Wright M, Isaacs P, Hashim A, Verma S. Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis. Aliment Pharmacol Ther. 2020 Jul;52(1):107-122. doi: 10.1111/apt.15802. Epub 2020 Jun 1. PMID: 32478917. Read it here >
Reduce (Results) Cooper M, Pollard A, Pandey A, Bremner S, Macken L, Evans CJ, Austin M, Parnell N, Steer S, Thomson S, Hashim A, Mason L, Verma S. Palliative Long-Term Abdominal Drains Versus Large Volume Paracentesis in Refractory Ascites Due to Cirrhosis (REDUCe Study): Qualitative Outcomes. J Pain Symptom Manage. 2021 Aug;62(2):312-325.e2. doi: 10.1016/j.jpainsymman.2020.12.007. Epub 2020 Dec 19. PMID: 33348031. Read it here >